Reasonable application of immunosuppressants in renal diseases: individual practice based on the guidelines

doi:10.3877/cma.j.issn.2095-3216.2014.04.001

Abstract

Abstract:

Immune disturbance is one of the most important mechanisms of glomerulonephropathy.Immunosuppressants play a critical role in the treatment of glomerulonephropathy. There are a variety of immunosuppressants. Different clinical and pathological manifestations in patients with glomerulonephropathy can reveal different responses to immunosuppressants. In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines standardized the indications, dosages, and courses of treatment with the immunosuppressants. In this paper, we summarized and discussed the applications of immunosuppressants in treatment of glomerulonephritis according to the KDIGO guidelines.

Key words: Immunosuppressant, Glomerulonephropathy, Guidelines

Ping Fu, Shenju Gou, Xi Tang. Reasonable application of immunosuppressants in renal diseases: individual practice based on the guidelines[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(04): 173-176.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.04.001

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I04/173

References 24

1	韩锐, 贾立华, 刘泽源, 等. 几种常见免疫抑制剂的研究进展[J]. 中国药业,2011,20(13):1-4.
2	Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults [J].Kidney Int,2011,80(8):868-878.
3	Goumenos DS, Tsagalis G, El Nahas AM,et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis:a five-year follow-up study [J]. Nephron Clin Pract, 2006, 104(2): c75-c82.
4	Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome [J]. Cochrane Database Syst Rev,2004, (4):CD004293.
5	Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome [J]. Nephrology(Carlton),2007,12(6):576-581.
6	Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy [J]. Lancet,2002,360(9337):923-924.
7	Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study[J]. J Am Soc Nephrol,2003,14(7):1851-1857.
8	Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses [J].Nephrol Dial Transplant,2004,19(5):1305-1307.
9	Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy [J]. Kidney Int, 1999, 56(4):1534-1543.
10	Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy [J]. Am J Kidney Dis,2006,47(2):233-240.
11	陈意志, 李平, 胡婕, 等. 新型免疫抑制剂治疗特发性膜性肾病的Meta 分析[J]. 中华肾病研究电子杂志,2014,3(2):91-98.
12	Tang S,Leung JC,Chan LY,et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int,2005,68(2):802-812.
13	Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy [J]. Kidney Int,2010,77(6):543-549.
14	Liang Y, Zhang J, Liu D, et al. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype [J]. Chin Med J (Engl), 2014, 127(1):102-108.
15	Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone [J]. Int J Clin Pharmacol Ther,2014,52(2):95-102.
16	Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study [J]. Kidney Int,2004,65(5):1842-1849.
17	Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial [J]. Kidney Int,2006,70(4):732-742.
18	Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study [J]. Lupus,2010,19(11):1281-1289.
19	Bao H, Liu ZH,Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy [J]. J Am Soc Nephrol,2008,19(10):2001-2010.
20	Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis [J]. N Engl J Med,2010,363(3):211-220.
21	Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis [J]. N Engl J Med,2010,363(3):221-232.
22	Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement [J]. Nephrol Dial Transplant,2008,23(4):1307-1312.
23	Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis[J]. Ann Rheum Dis,2009,68(3):310-317.
24	Li X, Tian J, Wu J, et al. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study [J]. Clin Ther,2009,31(4):741-750.

[1]	Yanmin Kan, Dong Wang, Jianmin Ding, Xiang Jing. Application of guidelines for standardized training and teaching activities for residents in ultrasound teaching [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(05): 537-541.
[2]	Yu Zhang, Song Yang. Interpretation of 2024 World Health Organization guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(03): 129-134.
[3]	Yu Wang, Fangquan Xu, Xuan Zhou, Xiaofeng Yao, Qiang Li. Improve the standardization of radical resection of differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 473-476.
[4]	Mingxing Guo, Ye Xu, Wanyi Xu, Ying Zhao, Ranjia Liu, Chen Pan, Xiangli Cui. Analysis of immunosuppressive drugs used in outpatient patients after kidney transplantation at 105 hospitals in China from 2017 to 2022 [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(02): 104-109.
[5]	Chunrong Ju, Jianxing He, Nanshan Zhong. The application and future prospects of mizoribine in the field of organ transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 227-231.
[6]	Luhao Liu, Yongxin Su, Lijuan Zeng, Peng Zhang, Rongxin Chen, Lu Xu, Guanghui Li, Jiali Fang, Junjie Ma, Zheng Chen. Drug compliance of immunosuppressant in kidney transplant recipients during the COVID-19 pandemic [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 140-145.
[7]	Zhihong Wei, Jianyong Liu, Xiaoya Wu, Fang Yang, Lizhi Lyu, Yi Jiang, Qiucheng Cai. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation （report of four cases） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 846-851.
[8]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[9]	Anti-cancer Association Colorectal Tumor Integrated Rehabilitation Committee， Neoadjuvant Therapy for Rectal Cancer Professional Committee of Beijing Cancer Prevention & Treatment Society Chinese. Guidelines on prevention，diagnosis，and treatment of nausea and vomiting caused by neoadjuvant therapies for rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(05): 353-361.
[10]	Yishan Zheng, Jun Yan, Jun Liu. Interpretation of the guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: neurology, peri-transplant medicine, infectious disease, and gastroenterology considerations [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(03): 214-217.
[11]	Nanqi Zhao, Xiaodong Wu, Dongxiao Mu, Nan Ding, Jing Hu. Analyzing the value of ancient clinicians' experience in acupuncture-moxibustion clinical practice guidelines [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2024, 13(04): 140-144.
[12]	Qin Li, Wei Mo, Bifang Zhou, Yulian Li, Xiuchun Yang. Construction of health problem list for patient guide after percutaneous hepatic puncture biliary drainage [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(04): 386-391.
[13]	Heqing Ye, Jie Li, Yuyuan Zhang, Luqi Hu, Bailu Wu, Xin Li, Shuwen Ye, Yifan Li, Yue Gao, Pengchao Zhan, Peijie Lv, Zhen Li. Efficacy of chemoembolization with drug-eluting bead combined with Donafenib and PD-1 in the treatment of advanced large liver cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(03): 212-216.
[14]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.
[15]	Zhiyong Dong, Cunchuan Wang. Interpretation of the 2022 ASMBS/IFSO Guidelines for Bariatric and Metabolic Surgery Indications [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(04): 225-230.

Please choose a citation manager

Content to export